Menopause Experts Issue First Comorbidity-Specific Guide to Non-Hormone Hot Flash Treatment
A 15-expert panel releases targeted guidance on non-hormone therapies for menopausal hot flashes, covering 13 comorbidities.
Summary
A multidisciplinary panel of 15 menopause specialists has released the first U.S. guidance specifically tailored to treating moderate-to-severe hot flashes and night sweats in women who cannot or choose not to use hormone therapy. The recommendations account for 13 comorbidities — including cardiovascular disease, cancer history, and autoimmune conditions — giving doctors and patients a clearer roadmap. Neurokinin-receptor antagonists like fezolinetant and elinzanetant are the recommended first-line options, with SSRIs, SNRIs, gabapentin, and oxybutynin as alternatives. Clonidine and most herbal remedies were excluded. The guidance was developed using a modified Delphi process and a systematic review of U.S. guidelines from 2014 to 2024, and was presented at the Endocrine Society's ENDO 2026 annual meeting.
Detailed Summary
Menopause is a universal biological transition, yet millions of women experiencing its most disruptive symptoms — hot flashes and night sweats — have historically lacked clear, personalized treatment guidance, especially when hormone therapy is not an option. A new consensus document aims to change that.
Presented at ENDO 2026, the annual Endocrine Society meeting, the guidance was developed by a 15-member multidisciplinary panel including ob/gyns, endocrinologists, and primary care physicians. Using a modified Delphi process and a systematic review of U.S. guidelines from 2014 to 2024, the group reached consensus on first- and second-line non-hormone treatments across 13 specific comorbidity categories — the first such comorbidity-specific framework in the United States.
Neurokinin (NK)-receptor antagonists, specifically fezolinetant (Veozah) and elinzanetant (Lynkuet), emerged as the preferred first-line therapies. These drugs target the brain's temperature-regulation pathways and carry strong clinical evidence. For women who cannot access or tolerate NK-receptor antagonists, SSRIs, SNRIs, gabapentin, and oxybutynin are recommended as second-line alternatives. Clonidine was excluded due to rebound hypertension risks, and most herbal or over-the-counter products were omitted given the availability of better-evidenced options.
The panel also introduced a MenoMEC (Menopause Medical Eligibility Criteria) tool designed to help clinicians match treatments to individual patient profiles based on comorbidities such as cardiovascular disease, cancer history, thrombosis risk, and metabolic conditions. Experts noted that general physician knowledge about menopause management remains insufficient, and these guidelines are intended to close that gap.
While the guidance represents a meaningful step forward, it is consensus-based rather than derived from new randomized controlled trials. Access to newer NK-receptor antagonists also remains limited in some settings. Women and clinicians should use this framework as a starting point for shared decision-making, ideally in consultation with a menopause-informed specialist.
Key Findings
- NK-receptor antagonists fezolinetant and elinzanetant are now recommended first-line non-hormone treatments for hot flashes.
- SSRIs, SNRIs, gabapentin, and oxybutynin serve as second-line options when NK-receptor antagonists are inaccessible or unsuitable.
- Clonidine was excluded from recommendations due to rebound hypertension risk.
- Guidance covers 13 comorbidities including cardiovascular disease, cancer history, thrombosis, and autoimmune conditions.
- A new MenoMEC tool helps clinicians personalize non-hormone therapy based on individual patient health profiles.
Methodology
This is a meeting coverage news report from MedPage Today summarizing a consensus guideline presented at ENDO 2026. The guidance was developed via a modified Delphi panel of 15 experts and a systematic review of U.S. guidelines from 2014–2024; it is consensus-based, not derived from new primary trial data.
Study Limitations
The guidance is consensus-based and does not represent new randomized controlled trial evidence, limiting its evidentiary strength. Access to first-line NK-receptor antagonists remains restricted in some healthcare settings. Full details of the MenoMEC tool and comorbidity-specific tables were not published in this news report and should be reviewed in the primary source document.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.